Digitalis Ventures

Digitalis is a venture capital firm founded in 2016 and headquartered in New York, New York, with additional offices in Boston, Los Angeles, and San Francisco. It focuses on investing in innovative solutions addressing complex challenges in human and animal health. Digitalis collaborates with entrepreneurs, inventors, and scientists at various stages of development, targeting companies within the healthcare, life sciences, and animal health sectors. The firm aims to support advancements in these fields by providing the necessary financial resources and expertise to foster growth and innovation.

Steve Allen

Partner

Cindy Cole

Technical Partner

Auro Nair

Partner

Dac Nguyen

Technical Partner

Victoria Perweiler

Venture Partner

Drew Taylor

Partner

Misti Ushio

Managing Partner

Past deals in Boston, MA

GRO Biosciences

Series A in 2021
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

GRO Biosciences

Seed Round in 2019
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

GRO Biosciences

Seed Round in 2018
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.